Business Context and Reporting Period
This Form 6-K filing by MediWound Ltd. covers the month of December 2022, specifically reporting on the effectiveness of a corporate action dated December 20, 2022. The Company, a foreign private issuer based in Yavne, Israel, filed this report to disclose the completion of a previously announced reverse share split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate action notice and does not contain financial performance data.
Material Changes
- Reverse Share Split: The Company effected a 1-for-7 reverse share split of its ordinary shares.
- Share Capital Adjustment: The authorized number of ordinary shares was reduced from 90,000,000 to 12,857,143.
- Par Value Increase: The par value per share increased proportionately from NIS 0.01 to NIS 0.07, maintaining the overall authorized share capital.
- Fractional Shares: Shareholders entitled to fractional shares received a whole number of shares after rounding up.
- Trading Details: The trading symbol remains "MDWD" on the Nasdaq Global Market, but a new CUSIP number (M68830 112) was assigned. Trading began on a reverse split-adjusted basis on December 20, 2022.
- Equity Plans: The number of shares available for grants, underlying outstanding awards, and exercise prices for options under equity incentive plans were adjusted to reflect the split.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook, or management commentary regarding future performance. It references a prior proxy statement (Exhibit 99.1 to a Form 6-K filed on October 21, 2022) for the rationale behind the split and its potential impact on the investment and market for the Company's shares. The filing notes that the split impacted all shareholders uniformly without altering percentage interests, except for negligible adjustments due to fractional share treatment.
Investor Verification Checklist
- Verify the new CUSIP number (M68830 112) for trading and record-keeping purposes.
- Confirm the adjusted number of shares held and the new par value (NIS 0.07) in brokerage accounts.
- Review the impact on outstanding equity awards, specifically the adjusted exercise prices and share counts.
- Check the Company's Form 20-F or subsequent filings for the financial results and liquidity position, as this 6-K does not contain them.